| Original language | English (US) |
|---|---|
| Pages (from-to) | 1154-1162 |
| Number of pages | 9 |
| Journal | Canadian Medical Association Journal |
| Volume | 179 |
| Issue number | 11 |
| DOIs | |
| State | Published - Nov 18 2008 |
Bibliographical note
Funding Information:Philip McFarlane has been a consultant to or an advisory board member of Ortho Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Pfizer, Novartis, AstraZeneca, Fresenius, Boehringer Ingelheim, Roche and Schering-Plough. He has received honoraria for presentations from Ortho-Biotech, Amgen, Sanofi-Aventis, Bristol-Myers Squibb, Biovail, Novartis, Abbott and Merck. Philip McFarlane has participated in or received research grant funding from Sanofi-Aventis, GlaxoSmithKline, Biovail, Boehringer Ingelheim, AstraZeneca, Ortho Biotech and Amgen.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS